BioMedNewsBreaks

TuesdayMar 30, 2021 11:04 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Multi-Omic Approach to New Drug Discovery

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and…

Continue Reading

MondayMar 29, 2021 3:29 pm

BioMedNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Medi-Scan Featured in BioWorld(TM) Article

Healthtech Solutions’ (OTC: HLTT) subsidiary, Medi-Scan Inc., was featured in a recent BioWorld(TM) article titled, “Medi-Scan’s digital tool converts ultrasound images to 3D at the point of care.” The piece discusses Medi-Scan’s cloud-based software that has the capability to rapidly (in less than two minutes) convert the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (“HD”) format. The company’s efforts currently focus on the heart and lungs, as it aims to provide quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including those suffering from COVID-19. Medi-Scan’s machine learning-based solution provides clinicians…

Continue Reading

MondayMar 29, 2021 1:35 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Featured in Latest Episode of Bell2Bell Podcast

United Medical Equipment (“UME,” “UMEBSNI”) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. UME’s President, Jason Pratt, and VP of Sales, Brian Gartland, joined the latest episode to discuss United Medical Equipment’s trusted-provider business model. “Every day, 10,000 people turn 65 in the United States. Having a home health background, I saw the need to have trusted resources for seniors and their families,” Pratt said in the interview. “A lot of home health care companies are only worried about their census, not about providing good…

Continue Reading

MondayMar 29, 2021 1:10 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Bringing Cost-Effective, Compact Solutions to Emergency Medicine

Brain Scientific (OTCQB: BRSF), with its low-cost, portable, wireless and easy-to-use electroencephalogram (“EEG”) devices, the NeuroCap(TM) and NeuroEEG(TM), has overcome the barriers preventing the use of EEGs in emergency settings. This means that patients and emergency departments can more readily realize numerous EEG benefits. An EEG can make the distinction between dementia and delirium, adequately determine the severity of a mild traumatic brain injury (“mTBI”), as well as identify nontraumatic causes of neurologic dysfunction such as syncope and vertigo. In contrast, head CTs or MRIs are not equipped to effectively perform any of these tasks, yet they are widely used.…

Continue Reading

MondayMar 29, 2021 11:53 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Featured in NetworkNewsAudio Broadcast

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” XPhyto CEO and Director Hugh Rogers…

Continue Reading

FridayMar 26, 2021 2:01 pm

BioMedNewsBreaks – RYAH Group Inc. Holds Key Distinction in Telehealth Era

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, appears ready to respond to strict data security requirements. This is an important distinction in an era where the use of telehealth solutions is exploding while securing the integrity of patient information remains critical. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is U.S. legislation surrounding requirements for medical providers to integrate privacy and security provisions to safeguard their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain and it is. Therefore, it is…

Continue Reading

FridayMar 26, 2021 12:29 pm

BioMedNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Breakthrough Technology Rectifies Cystoscopy Limitations

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed proprietary technology that solves the issues associated with existing cystoscopies. “White light images show the full landscape of the bladder but do not effectively highlight cancer,” reads an article about the benefits of the i/Blue Imaging(TM) System, Imagin Medical’s proprietary technology. “A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light. However, surgeons can’t operate using blue light images. The blue images aren’t in real-time, orientation in the bladder is easily lost, and the surgeon…

Continue Reading

FridayMar 26, 2021 9:58 am

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2020 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 was the selection of five U.S. clinical sites for the enrollment of patients for the company’s upcoming phase 2B trial; exclusive licensing agreements with Elion Oncology Inc. and Yuhan Corporation; the appointment of new board and executive team members; and the closing of an underwritten…

Continue Reading

FridayMar 26, 2021 9:26 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q4, FY 2020 Financial, Operational Results

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant achievements for the company was a full-year revenue increase of 15%; revenue for 2020 was $13.1 million compared to $11.4 million in 2019. Gross profit and margin was up for both the fourth quarter and…

Continue Reading

ThursdayMar 25, 2021 2:29 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Continues to Advance Toward Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol. The protocol will be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”). This new development set the wheels in motion for the eventual approval of WPD’s studies — a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial. “WPD plans to…

Continue Reading